Bita Fakhri, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fakhri’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A152281 · Current
Licensed to practise in California · since 2017 · expires 2027-04-30 · Iran Medical Centre Aka Iran University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$117,076
Medicare paid this office $117,076 for 307 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 120 | $33,776 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $33,211 | $106 |
| Long return visit (40+ min) | 89 | $19,321 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,594 | $151 |
| Return visit (30+ min) | 47 | $6,775 | $119 |
See all 9 services
| Long return visit (40+ min) | 120 | $33,776 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $33,211 | $106 |
| Long return visit (40+ min) | 89 | $19,321 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,594 | $151 |
| Return visit (30+ min) | 47 | $6,775 | $119 |
| New patient visit (60+ min) | 40 | $6,029 | $151 |
| Hospital discharge day management, more than 30 minutes | 40 | $4,480 | $104 |
| New patient visit (60+ min) | 15 | $2,961 | $197 |
| Return visit (30+ min) | 19 | $1,497 | $71 |
Who their Medicare patients are
307 Original Medicare patients in 2024. Average age 76 · Women 39% · Also on Medicaid 13% · Health risk score 2.14. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 67% · Coronary heart disease 33% · Atrial fibrillation 28% · Chronic kidney disease 26% · Diabetes 22% · Heart failure 21% · Cancer 19% · Depression 14% · COPD 12% · Stroke 10% · Dementia 9%.
The office billed $501,351, Medicare allowed $156,201 and paid $117,076; for 940 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 307 | 940 | 76 | 2.14 | $501,351 | $117,076 |
| 2023 | 240 | 689 | 75 | 2.16 | $372,153 | $81,667 |
| 2022 | 225 | 578 | 73 | 2.49 | $420,121 | $47,766 |
| 2021 | 172 | 524 | 73 | 2.51 | $420,444 | $60,928 |
| 2020 | 153 | 572 | 72 | 2.60 | $463,195 | $52,937 |
| 2019 | 135 | 437 | 72 | 2.47 | $439,413 | $40,914 |
| 2018 | 44 | 56 | 70 | 2.18 | $49,536 | $6,477 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 161 | $42,030 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $24,030 | $107 |
| New patient visit (60+ min) | 48 | $7,334 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,128 | $160 |
| Hospital discharge day management, more than 30 minutes | 20 | $2,237 | $107 |
2022: 4 services
| Long return visit (40+ min) | 155 | $25,929 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $7,224 | $89 |
| New patient visit (60+ min) | 19 | $3,161 | $166 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 19 | $1,031 | $52 |
2021: 4 services
| Long return visit (40+ min) | 126 | $46,940 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $5,171 | $92 |
| New patient visit (60+ min) | 33 | $5,024 | $152 |
| Return visit (30+ min) | 16 | $1,439 | $90 |
2020: 4 services
| Long return visit (40+ min) | 94 | $29,770 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $7,989 | $94 |
| Return visit (30+ min) | 62 | $6,060 | $66 |
| New patient visit (60+ min) | 34 | $4,991 | $147 |
2019: 4 services
| Long return visit (40+ min) | 72 | $17,053 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $8,462 | $92 |
| New patient visit (60+ min) | 47 | $6,507 | $138 |
| Return visit (30+ min) | 45 | $4,687 | $70 |
2018: 2 services
| New patient visit (60+ min) | 21 | $3,129 | $149 |
| Long return visit (40+ min) | 21 | $2,452 | $98 |
Medicaid work
$9,794 in 2024
Medicaid paid $9,794 for 175 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 175 | $9,794 |
| 2024 | 175 | 1 | 15 | $9,794 |
| 2022 | 46 | 3 | 13 | $3,641 |
| 2021 | 52 | 1 | 15 | $7,877 |
| 2020 | 13 | 1 | 12 | $1,351 |
See the largest Medicaid services in earlier years
2022
| Long return visit (40+ min) | 17 | $1,905 |
| COMPREHENSIVE METABOLIC PANEL | 14 | $1,243 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 15 | $493 |
2021
| Long return visit (40+ min) | 52 | $7,877 |
2020
| Long return visit (40+ min) | 13 | $1,351 |
Drugs they prescribed that Part D paid
$1,181,874
Pharmacies billed $1,181,874 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 150) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
77 generic and 73 brand-name prescriptions · $1,181,874 in drug cost · 23 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jaypirca | 18 | $487,039 | $27,058 |
| Brukinsa | 21 | $275,222 | $13,106 |
| Imbruvica | 13 | $199,209 | $15,324 |
| Calquence | 11 | $155,288 | $14,117 |
| Acyclovir | 16 | $230 | $14 |
See all 6 drugs
| Jaypirca | 18 | $487,039 | $27,058 |
| Brukinsa | 21 | $275,222 | $13,106 |
| Imbruvica | 13 | $199,209 | $15,324 |
| Calquence | 11 | $155,288 | $14,117 |
| Acyclovir | 16 | $230 | $14 |
| Levofloxacin | 17 | $124 | $7 |
Year by year
| 2024 | 150 | 51 | 0% (0) | 49% | $1,181,874 |
| 2023 | 126 | 50 | 0% (0) | 54% | $1,037,684 |
| 2022 | 231 | 62 | 0% (0) | 50% | $1,338,053 |
| 2021 | 505 | 68 | None | 34% | $2,084,217 |
| 2020 | 522 | 76 | 3% (14) | 32% | $2,229,843 |
| 2019 | 342 | 57 | 6% (20) | 25% | $1,007,109 |
| 2018 | 30 | None | 0% (0) | None | $55,879 |
| 2016 | 31 | 16 | None | None | $1,111 |
| 2015 | 220 | 23 | None | None | $6,235 |
| 2014 | 220 | 32 | 0% (0) | None | $9,471 |
| 2013 | 298 | 48 | 4% (11) | None | $21,574 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Calquence | 31 | $455,384 | $14,690 |
| Jaypirca | 13 | $298,938 | $22,995 |
| Brukinsa | 15 | $227,344 | $15,156 |
| Levofloxacin | 11 | $209 | $19 |
2022: 4 drugs
| Calquence | 29 | $417,143 | $14,384 |
| Brukinsa | 19 | $266,851 | $14,045 |
| Imbruvica | 16 | $247,524 | $15,470 |
| Acyclovir | 38 | $1,048 | $28 |
2021: 12 drugs
| Imbruvica | 46 | $669,665 | $14,558 |
| Calquence | 39 | $526,964 | $13,512 |
| Brukinsa | 23 | $307,086 | $13,352 |
| Revlimid | 15 | $287,427 | $19,162 |
| Xarelto | 11 | $5,708 | $519 |
| Acyclovir | 105 | $1,738 | $17 |
| Omeprazole | 19 | $374 | $20 |
| Ondansetron | 20 | $299 | $15 |
| Prednisone | 20 | $197 | $10 |
| Entecavir | 11 | $156 | $14 |
| Sulfamethoxazole-Trimethoprim | 19 | $97 | $5 |
| Lorazepam | 18 | $65 | $4 |
2020: 14 drugs
| Imbruvica | 53 | $719,450 | $13,575 |
| Revlimid | 36 | $625,562 | $17,377 |
| Calquence | 30 | $448,016 | $14,934 |
| Venclexta | 18 | $221,587 | $12,310 |
| Atovaquone | 14 | $8,892 | $635 |
| Entecavir | 11 | $3,626 | $330 |
| Acyclovir | 119 | $1,846 | $16 |
| Dapsone | 13 | $1,043 | $80 |
| Valacyclovir | 12 | $690 | $57 |
| Ondansetron | 15 | $261 | $17 |
| Prednisone | 24 | $219 | $9 |
| Dexamethasone | 12 | $169 | $14 |
| Sulfamethoxazole-Trimethoprim | 27 | $116 | $4 |
| Lorazepam | 11 | $55 | $5 |
2019: 10 drugs
| Revlimid | 32 | $509,748 | $15,930 |
| Imbruvica | 26 | $327,920 | $12,612 |
| Atovaquone | 11 | $6,246 | $568 |
| Acyclovir | 54 | $848 | $16 |
| Oxycodone | 11 | $389 | $35 |
| Dexamethasone | 13 | $219 | $17 |
| Ondansetron | 17 | $210 | $12 |
| Prednisone | 23 | $154 | $7 |
| Sulfamethoxazole-Trimethoprim | 18 | $57 | $3 |
| Lorazepam | 12 | $38 | $3 |
2015: 3 drugs
| Amlodipine Besylate | 32 | $123 | $4 |
| Metformin | 15 | $76 | $5 |
| Glipizide | 12 | $46 | $4 |
2014: 4 drugs
| Amlodipine Besylate | 39 | $174 | $4 |
| Gabapentin | 14 | $121 | $9 |
| Hydrochlorothiazide | 18 | $62 | $3 |
| Lisinopril | 11 | $50 | $5 |
2013: 8 drugs
| Metoprolol | 40 | $1,755 | $44 |
| Atorvastatin | 14 | $658 | $47 |
| Torsemide | 13 | $335 | $26 |
| Lisinopril | 36 | $259 | $7 |
| Isosorbide Mononitrate Er | 11 | $197 | $18 |
| Amlodipine Besylate | 21 | $148 | $7 |
| Simvastatin | 14 | $90 | $6 |
| Furosemide | 18 | $64 | $4 |
Money from drug and device companies
$21,686 in 2025
| 2025 | 5 | 22 | $18,130 | $21,686 |
| 2024 | 3 | 42 | $44,579 | $48,107 |
| 2023 | 8 | 47 | $62,150 | $65,133 |
| 2022 | 7 | 13 | $13,591 | $14,957 |
| 2021 | 3 | 5 | $5,225 | $5,252 |
| 2020 | 4 | 10 | $8,238 | $9,198 |
| 2019 | 4 | 11 | $4,850 | $6,360 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Venclexta | $14,754 | 14 payments
|
| Genentech USA | Rituxan | $3,554 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $2,010 | 1 payment
|
| Secura Bio | Copiktra | $1,320 | 1 payment
|
| Janssen Biotech | Imbruvica | $48 | 1 payment
|
See all 22 published payments
| Abbvie | Consulting · 2025-12-18 | None | $1,500 |
| Abbvie | Meals · 2025-12-06 | Venclexta | $55 |
| Abbvie | Meals · 2025-12-06 | Venclexta | $15 |
| Janssen Biotech | Meals · 2025-12-05 | Imbruvica | $48 |
| Abbvie | Meals · 2025-12-05 | Venclexta | $123 |
| Abbvie | Meals · 2025-12-05 | Venclexta | $25 |
| Abbvie | Consulting · 2025-11-26 | Venclexta | $2,250 |
| Abbvie | Consulting · 2025-11-26 | Venclexta | $3,000 |
| Abbvie | Consulting · 2025-11-26 | Venclexta | $3,000 |
| Abbvie | Travel · 2025-10-07 | Venclexta | $392 |
| Abbvie | Travel · 2025-10-06 | Venclexta | $693 |
| Abbvie | Travel · 2025-10-06 | Venclexta | $701 |
| Genentech USA | Travel · 2025-05-30 | Rituxan | $165 |
| Genentech USA | Travel · 2025-05-30 | Rituxan | $413 |
| Genentech USA | Consulting · 2025-05-30 | Rituxan | $2,050 |
| Genentech USA | Meals · 2025-05-30 | Rituxan | $232 |
| Genentech USA | Travel · 2025-05-30 | Rituxan | $693 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-05-20 | Calquence | $2,010 |
| Abbvie | Consulting · 2025-03-25 | Venclexta | $750 |
| Abbvie | Consulting · 2025-02-26 | Venclexta | $750 |
| Secura Bio | Paid to speak or teach · 2025-02-13 | Copiktra | $1,320 |
| Abbvie | Consulting · 2025-01-30 | None | $1,500 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $48,107
| Lilly USA | Jaypirca | $23,399 | 19 payments
|
| Abbvie | Venclexta | $21,486 | 16 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $3,222 | 7 payments
|
2023: $65,133
| Lilly USA | Jaypirca | $29,422 | 18 payments
|
| Abbvie | Venclexta | $23,091 | 20 payments
|
| Janssen Biotech | Imbruvica | $3,240 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $2,081 | 1 payment
|
| Genentech USA | Lunsumio | $1,932 | 2 payments
|
| BeiGene USA | Brukinsa | $1,875 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,779 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $1,713 | 2 payments
|
2022: $14,957
| Abbvie | Venclexta | $5,170 | 4 payments
|
| Eli Lilly and | None | $4,381 | 2 payments
|
| Genentech USA | Venclexta | $1,765 | 1 payment
|
| Janssen Scientific Affairs | Imbruvica | $1,515 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,194 | 2 payments
|
| CSL Behring | Hizentra | $900 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $33 | 1 payment
|
2021: $5,252
| CSL Behring | Hizentra | $3,600 | 3 payments
|
| BeiGene USA | None | $1,625 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $27 | 1 payment
|
2020: $9,198
| AstraZeneca Pharmaceuticals LP | Calquence | $3,735 | 7 payments
|
| Amgen | Blincyto | $2,400 | 1 payment
|
| Epizyme | Tazverik | $1,813 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $1,250 | 1 payment
|
2019: $6,360
| Pharmacyclics LLC An AbbVie | Imbruvica | $3,074 | 7 payments
|
| Eli Lilly and | None | $1,650 | 1 payment
|
| Seattle Genetics | Adcetris | $1,625 | 2 payments
|
| Genentech USA | Venclexta | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| BeiGene, Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2025 | Their institution | $1,458,453 |
| Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2024 | Their institution | $1,302,382 |
| Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2025 | Their institution | $935,502 |
| BeiGene, Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2024 | Their institution | $666,614 |
| BeOne Medicines Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2025 | Their institution | $307,598 |
| ABBVIE INC. · Study To Evaluate Adverse Events Change in Disease Activity and How Oral Abbv-101 Moves Through the Body in Adult Participants With B-Cell Malignancies · 2025 | Their institution | $277,018 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2021 | Their institution | $262,298 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2022 | Their institution | $258,366 |
| BeOne Medicines Ltd. · A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-Cd20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2025 | Their institution | $218,865 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2020 | Their institution | $200,526 |
| ABBVIE INC. · Study To Evaluate Adverse Events Change in Disease Activity and How Oral Abbv-101 Moves Through the Body in Adult Participants With B-Cell Malignancies · 2024 | Their institution | $166,886 |
| Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2024 | Their institution | $149,009 |
| ABBVIE INC. · First-in-Human Study To Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the Btk Degrader, Abbv-101, in Participants With B-Cell Malignancies · 2025 | Their institution | $136,061 |
| Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subje - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2022 | Their institution | $114,215 |
| BeOne Medicines USA, Inc. · A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-Cd20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2025 | Their institution | $108,304 |
| Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subje · 2021 | Their institution | $81,598 |
| Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2023 | Their institution | $46,178 |
| Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2025 | Their institution | $41,604 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2019 | Their institution | $2,884 |
| ABBVIE INC. · Multicenter, Evaluator-Blinded, Randomized, Controlled Study of the Safety and Effectiveness of Juvederm Volite Xc Injectable Gel for Improvement in Neck Appearance · 2025 | Their institution | $1,780 |
| Eli Lilly and Company · A Phase 3 Open-Label Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2023 | This clinician | $1,333 |
| Eli Lilly and Company · A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With A Covalent Bruton Tyrosine Kinase Inhibitor · 2024 | Their institution | $1,307 |
| ABBVIE INC. · M23-647 Abbv-101 Ph1 Rr Nhl Fih · 2024 | Their institution | $1,221 |
| Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2024 | This clinician | $900 |
| ABBVIE INC. · First-in-Human Study To Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the Btk Degrader, Abbv-101, in Participants With B-Cell Malignancies · 2024 | Their institution | $672 |
| Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2023 | Their institution | $206 |
| ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2025 | Their institution | $128 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568729424
- Licence
- CA A152281California A152281: Current · expires 2027-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2012-04-17
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 400 Parnassus Ave, San Francisco, CA, 94143